Astex Pharmaceuticals, Inc. (ASTX) - NASDAQ
ASTX is defunct.
  • Sep. 4, 2013, 1:48 PM
    Astex Pharmaceuticals (ASTX +30%) soars on reports that it will be acquired by Otsuka Pharma in Japan for ¥90B.
    | Sep. 4, 2013, 1:48 PM
  • Aug. 30, 2013, 11:39 AM
    • Astex Pharmaceuticals (ASTX -4.1%) is notably weak today after running up ~25% on Wednesday following topline data from a Phase 2 trial of SGI-110.
    • Not helping the stock's cause is an article from theStreet's Adam Feuerstein who takes issue with RBC analyst Michael Yee's bullish thesis.
    • "Concluding that SGI-110 is better than Dacogen [another ASTX product which is licensed to Eisai (ESALF.PK)] based on an interim look at just 17 patients is silly," Feuerstein says, adding that the observed 53% response rate in the cohort of elderly patients with treatment-naive AML "will not hold up once the cohort ... reaches full enrollment."
    • Ultimately, Feuerstein thinks it's "premature to say much of anything about SGI-110's activity in AML relative to Dacogen based on the paltry and incomplete data released ... on Wednesday."
    • For the record, the company says it released interim results because "the data was material and ASH just cleared [the company] for top-line data release without violating the embargo."
    | Aug. 30, 2013, 11:39 AM | 1 Comment
  • Aug. 28, 2013, 12:45 PM
    | Aug. 28, 2013, 12:45 PM
  • Aug. 28, 2013, 12:27 PM
    • Astex Pharmaceutical (ASTX) continues to run, now up more than 23% following positive topline results from Phase II trials of its SGI-110 drug candidate in patients with acute myelogenous leukemia and myelodysplastic syndromes.
    | Aug. 28, 2013, 12:27 PM
  • Aug. 28, 2013, 9:11 AM
    | Aug. 28, 2013, 9:11 AM
  • Aug. 28, 2013, 7:37 AM
    • Astex Pharmaceuticals' (ASTX) SGI-110 "showed clear activity in patients with acute myeloid leukemia" in Phase II testing.
    • The overall remission rate in 67 subjects was 25%.
    • However, no results were provided for patients with Myelodysplastic syndromes (MDS), a group of blood and bone marrow disorders, who were also part of the trial.
    • Shares +12.2%.
    | Aug. 28, 2013, 7:37 AM
  • Aug. 9, 2013, 5:31 PM
    | Aug. 9, 2013, 5:31 PM | 1 Comment
  • Jul. 22, 2013, 11:02 AM

    Astex Pharmaceuticals (ASTX -2.6%) slips despite presenting data which suggests the HSP90 inhibitor AT13387 delayed the emergence of resistance in mice in a preclinical model of mutant BRAF melanoma. The mice were treated with vemurafenib alone and in combination with AT13387. Mice which received the combination treatment did not exhibit tumor regrowth. (PR)

    | Jul. 22, 2013, 11:02 AM
  • Jul. 8, 2013, 10:52 AM

    Astex Pharmaceuticals (ASTX +3.6%) jumps after the company says it plans to submit an IND for ASTX727 (a combo of decitabine and the cytidine deaminase inhibitor E7727) in Q4. (PR)

    | Jul. 8, 2013, 10:52 AM
  • Jun. 14, 2013, 8:40 AM

    Astex Pharmaceuticals (ASTX) jumps 4% before the bell after saying treatment with the hypomethylating agent, SGI-110 produced an overall clinical response rate of 40% in patients with heavily pre-treated myelodysplastic syndrome (preleukemia). (PR)

    | Jun. 14, 2013, 8:40 AM
  • Jun. 10, 2013, 5:30 PM
    After-hours top gainers, as of 5:15 p.m.: BEAT +36%. CTRX +14%. CYS +3%. KNDI +3%. GME +3%.
    After-hours top losers: LULU -11%. ASTX -6%. XTEX -4%. COCO -4%. PBY -3%.
    | Jun. 10, 2013, 5:30 PM | 1 Comment
  • May 24, 2013, 5:42 PM
    After-hours top gainers, as of 5:15 p.m.: SIGA +23%. FXEN +7%. LPSN +5%. QSII +4%. STRZA +3%.
    After-hours top losers: XNPT -7%. DF -6%. ASTX -4%. SPWR -3%. FNSR -2%.
    | May 24, 2013, 5:42 PM
  • May 8, 2013, 1:25 PM

    Astex Pharmaceutical (ASTX -4.4%) succumbs to profit-taking for a second day on heavy volume, with no real catalyst to explain the move but some small sales reported by its CEO and one of its directors over the past couple days. The sales really aren't too surprising when you take into consideration that the stock has been on a tear since late last year, rising over 225% just since November.

    | May 8, 2013, 1:25 PM | 2 Comments
  • May 1, 2013, 12:50 PM
    Midday top 10 gainers: IQNT +60%. BCOV +31%. CNIT +28%. MNOV +21%. MSPD +19%. SONS +15%. TRLA +15%. RATE +15%. REGN +14%. SGI +14%.
    Midday top 10 losers: ACCL -21%. RBC -20%. ESBF -17%. LEDS -16%. KFRC -15%. AGN -14%. CRAY -13%. ASTX -13%. XXIA -13%. UTI -12%.
    | May 1, 2013, 12:50 PM
  • Apr. 10, 2013, 8:46 AM

    Astex Pharmaceuticals (ASTX) looks set for a strong session after saying researchers at Indiana University found that the company's SGI-110 DNA-hypomethylating agent "significantly" slowed tumor growth when administered with platinum. Earlier this month, RBC called the drug a "potential blockbuster." ASTX also notes it has expanded an ongoing Phase 2 trial. Shares +2.38% premarket. 

    | Apr. 10, 2013, 8:46 AM
  • Apr. 3, 2013, 11:51 AM

    Astex Pharmaceuticals (ASTX +12.5%) gets a pop from RBC today, who initiated coverage with an Outperform and a $9 price target, calling it an "undiscovered gem." The firm says the ASTX could have a blockbuster in its pipeline with its experimental blood cancer drug, SGI-110, which is thought to be a safer and more effective version of an already approved therapy it licenses to Eisai (ESALY.PK) and JNJ. ASTX owns all the rights to SGI-110, giving it big upside potential if it gets approved. Additionally, the company reported earlier that it plans to present "significant data" at the AACR annual meeting on Saturday.

    | Apr. 3, 2013, 11:51 AM
Company Description
We are a pharmaceutical company dedicated primarily to the discovery and development of therapies to treat patients with cancer. Historically we acquired products that were developed by other companies and applied additional developmental effort to expand sales or advance these products... More
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States